New Thyroid Cancer Therapy Tops SPT Week in Review
Top news of the week from Specialty Pharmacy Times.
5. FDA Grants Fast Track Designation to Potential Chikungunya Virus Vaccine
PaxVax, an independent specialty vaccine company, is developing the prophylaxis.
4. Immunotherapy Slows Progression of Chronic Lymphocytic Leukemia
A dual immune-checkpoint blockade efficiently controlled the development of chronic lymphocytic leukemia by restoring functional antitumor immune response.
3. How Artificial Intelligence Can Change the Pharmacy Landscape
Artificial intelligence could take over medication dispensing in the next 50 years.
2. Targeted Chemotherapy, Genetic Testing Could Change How BRCA-Mutated Breast Cancer Is Treated
Researchers found that women with advanced triple-negative breast cancer who had inherited a BRCA mutation benefited more from the chemotherapy carboplatin than standard treatment.
1. FDA Approves Combo Therapy for BRAF-Positive Anaplastic Thyroid Cancer
The combination therapy dabrafenib plus trametinib approved for the treatment of BRAF V600 mutation-positive anaplastic thyroid cancer that cannot be removed by surgery or is metastatic.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Related Articles
Effectively Managing Immunizations in the Long-Term Care SettingSeptember 18th 2025
Creating a Culture of Quality in Fast-Melt Tablet DevelopmentSeptember 18th 2025
Advise Patients About Self-Care Measures to Treat Mild to Moderate GI IssuesSeptember 18th 2025
